Integrated Biopharma INC

Integrated BioPharma, Inc. and its subsidiary Manhattan Drug Company, Inc. have amended their loan agreement with PNC Bank, extending a revolving line of credit and establishing a new convertible line of credit.

Integrated BioPharma, Inc. reported a net loss of $0.8 million for the quarter ended March 31, 2026, driven by a 27.3% decline in quarterly revenue.

Integrated BioPharma, Inc. announced an extension of its credit line with PNC Bank, moving the expiration date to July 14, 2026.

Integrated BioPharma, Inc. reported a net loss of $0.8 million for the quarter ended December 31, 2025, as revenue decreased by 10.3% to $11.3 million.

Integrated BioPharma, Inc. announced the results of its 2025 Annual Meeting, where stockholders elected a Class III director, approved executive compensation, and ratified the independent auditors.

Integrated BioPharma, Inc. reported a 6.6% decrease in revenue to $12.7 million for the quarter ended September 30, 2025, alongside declines in operating and net income.

Integrated BioPharma reports a net loss of $0.8 million for the third quarter of 2026 amid declining sales and high customer concentration.

Integrated BioPharma, Inc. reported a net loss for the quarter and six months ended December 31, 2025, driven by significant sales decreases and margin erosion.

Integrated BioPharma, Inc. reported a significant drop in net income and sales for the first quarter of fiscal year 2026, primarily due to decreased volumes from major contract manufacturing customers.

Integrated BioPharma reports increased sales and profitability for the third quarter of 2025, driven by growth in both its Contract Manufacturing and Other Nutraceutical Businesses segments.

Integrated BioPharma, Inc. reports a 7% increase in net sales and a significant improvement in operating income for the six months ended December 31, 2024, compared to the same period in 2023.

Integrated BioPharma, Inc. reports a profitable quarter with increased sales and improved margins, despite ongoing challenges from inflation and supply chain issues.

Integrated BioPharma, Inc. reported an 8% increase in net sales and a significant rise in net income for the fiscal year ended June 30, 2025, driven by growth in both Contract Manufacturing and Other Business Lines segments.

Integrated BioPharma experienced a minor decrease in revenue but achieved net income in fiscal year 2024, according to its latest 10-K filing.

Eric J. Friedman, a Director at Integrated Biopharma Inc., has acquired 50,000 stock options with an exercise price of $0.19.

Damon DeSantis, Director and 10% Owner of Integrated Biopharma Inc., acquired 50,000 stock options on June 24, 2026.

Eric J. Friedman, a Director at Integrated Biopharma Inc., has acquired 50,000 stock options with an exercise price of $0.19.

Robert Canarick, a Director at Integrated Biopharma Inc., has acquired 50,000 stock options with an exercise price of $0.19.

William H. Milmoe, a Director at Integrated Biopharma Inc., has acquired 50,000 stock options with an exercise price of $0.19.

Director William H. Milmoe filed an amended Form 4 to correct the transaction date for the transfer of Integrated Biopharma, Inc. shares to CDDS 2.0, LLC.

Integrated BioPharma, Inc. announces its 2025 Annual Meeting to address director election, executive compensation, and auditor ratification.

Integrated BioPharma, Inc. will hold its 2024 Annual Meeting of Stockholders on December 2, 2024, to elect directors and ratify the appointment of its independent auditor.

The reporting group, including the estate of Carl DeSantis, has ceased beneficial ownership of Integrated BioPharma, Inc. shares.

Damon DeSantis and CDDS 2.0, LLC have reported a combined 41.3% beneficial ownership stake in Integrated Biopharma, Inc. following a series of internal share transfers.